Pfiz­er puts the pres­sure on Eli Lil­ly's JAK in­hibitor Olu­mi­ant with new da­ta in alope­cia area­ta

As Eli Lil­ly looks to se­cure a win for its block­buster Olu­mi­ant in alope­cia area­ta, go­ing where no JAK in­hibitor has gone be­fore, Pfiz­er is com­ing up from be­hind with Phase IIb/III re­sults sug­gest­ing its own can­di­date can help re­grow hair lost due to the au­toim­mune dis­ease.

On Wednes­day, Pfiz­er un­veiled topline re­sults from the AL­LE­GRO tri­al, which en­rolled 718 pa­tients 12 years and old­er with alope­cia area­ta, a con­di­tion that can cause sud­den, se­vere and patchy hair loss. While the pa­tients’ episodes of alope­cia area­ta var­ied in length, they all had one thing in com­mon: They had lost at least half the hair on their scalps.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER